Iovance Biotherapeutics Inc

iovance.com

What Do They Do?

Sells an individualized T-cell therapy for adults with previously treated advanced melanoma, plus a medicine used in its treatment regimen and other cancer applications.

How Do They Make Money?

Hospitals, clinics and distributors buy its products, with payment timing varying by customer and product. Amtagvi sales are counted when a patient receives the infusion; Proleukin sales are counted when shipped or delivered.

revenue

Segment	Share	Revenue	How money arrives
Amtagvi Sold outright	84%		Sold outright
PROLEUKIN Sold outright	17%		Sold outright

Who Are Their Customers?

Hospitals and clinics buy directly, while distributors and wholesalers also buy the products; Proleukin is also sold to distributors abroad and other third-party clients.

Do Revenues Turn Into Profits?

No. It lost $391M in FY2025.

Operating income, FY2025

−153% of revenue

▲ +2% (Loss) vs FY2024 (−$395.3M, −241%)

Net income, FY2025

−148% of revenue

▲ +5% (Loss) vs FY2024 (−$372.2M, −227%)

Free cash flow, FY2025

−128% of revenue

▼ −8% (Loss) vs FY2024 (−$364M, −222%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +66%; vs $60M in Q2 FY2025
Net income: ▼ −58% (Loss); vs −$111.7M in Q2 FY2025

Amtagvi share of revenue vs 90.2% in Q2 FY2025

Aug 6, 2026 Iovance reviews full-year revenue guidance It said an update would follow during the third quarter.
Jun 10, 2026 Amtagvi receives marketing approval in Australia Australia approved the treatment for previously treated advanced melanoma.

From candidate to commercial products The older report described lifileucel as a product candidate with a pending U.S. approval application; the latest presents Amtagvi and Proleukin as commercial products and describes Amtagvi's U.S. launch.

Revenue over time

Amtagvi PROLEUKIN

$500M$250M$0

FY2023 FY2024 FY2025

Comments